<?xml version="1.0" encoding="UTF-8"?>
<p id="par0175">Since the first reports of SARS, it seemed clear that the severe clinical manifestations of the disease could not be ascribed only to the viral activity 
 <italic>per se</italic>, but that an immune-mediated mechanism rather than a direct virus-induced damage would drive the clinical progression [
 <xref rid="bib0335" ref-type="bibr">67</xref>]. Indeed from the physio-pathology point of view, the most interesting observation was the demonstration that viral titers seemed to paradoxically diminish during the most severe phase of the disease both in humans and in several animal models [
 <xref rid="bib0005" ref-type="bibr">1</xref>]. Data coming from patients’ series described during the 2003–2004 epidemics clearly suggested that complex alterations in the chemokine system were related to the outcome of SARS-CoV infection (
 <xref rid="fig0005" ref-type="fig">Fig. 1</xref> ).
</p>
